Understanding the impacts of COVID-19 pandemic in people with multiple sclerosis treated with ocrelizumab
- 6 August 2021
- journal article
- research article
- Published by Elsevier BV in Multiple Sclerosis and Related Disorders
- Vol. 55, 103203
- https://doi.org/10.1016/j.msard.2021.103203
Abstract
No abstract availableThis publication has 27 references indexed in Scilit:
- Genetic profile and clinical characteristics of Chinese patients with spinocerebellar ataxia type 2: A multicenter experience over 10 yearsEuropean Journal of Neurology, 2020
- Effect of ocrelizumab on vaccine responses in patients with multiple sclerosisNeurology, 2020
- SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognitionNature Immunology, 2020
- COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responsesNature, 2020
- Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease SeverityCell, 2020
- Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple SclerosisJAMA Neurology, 2020
- COVID-19 in people with multiple sclerosis: A global data sharing initiativeMultiple Sclerosis Journal, 2020
- COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?Multiple Sclerosis and Related Disorders, 2020
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple SclerosisThe New England Journal of Medicine, 2017
- Ocrelizumab versus Placebo in Primary Progressive Multiple SclerosisThe New England Journal of Medicine, 2017